PLOS One retracts mouse osteolysis paper after image integrity concerns
PLOS One has retracted a 2013 mouse study that examined whether pyrroloquinoline quinine could inhibit RANKL-mediated NFATc1 expression and reduce wear particle-induced osteolysis. The retraction centers on multiple image irregularities across the paper’s figures, including repeated features within and between panels, apparent duplication across different experimental conditions, and several panels that partially overlapped with images from a separate publication. Those problems were serious enough to call the reliability of the published results into question.
The paper had focused on a mechanistic pathway central to bone resorption. RANKL-driven osteoclast differentiation depends on signaling cascades that converge on NFATc1, a transcription factor that helps drive the formation and activity of osteoclasts. In the context of wear particle-induced osteolysis, that biology matters because excessive osteoclast activation can contribute to bone loss around implants. The retracted article claimed to show that pyrroloquinoline quinine could suppress this pathway in mouse bone marrow cells and blunt osteolysis in mice.
The editorial action did not hinge on a single isolated problem. Concerns were raised about figures 1, 2, and 5, with multiple panels showing signs of repetition or overlap. In Fig 1A, there appeared to be multiple repetitive features within and/or between all panels. In Fig 2D, the NFATc1 panel appeared similar to a NFATc1 panel in a different paper despite representing different experimental conditions. Several panels in Fig 5 also appeared to overlap, including image pairs that matched when flipped. Two panels within Fig 5 were also flagged as appearing similar to one another.
Those visual concerns matter because image-based experimental data often carry the burden of supporting the story built in the text. When a blot, microscopy image, or other panel is reused or manipulated across conditions, the problem is not cosmetic. It can alter the interpretation of pathway activity, cell behavior, and treatment effect. In a mechanistic paper centered on a signaling axis such as NFATc1, the credibility of the pathway claim depends on the integrity of the underlying figures.
One sentence captures the entire editorial decision: the published results can no longer be trusted.
The retraction notice also states that all authors either did not respond directly or could not be reached. That absence left the editors without a corrective explanation, replacement data, or a documented resolution to the figure concerns. In practice, that means the article remains part of the scholarly record only as a retracted publication, with its conclusions withdrawn from active use in the literature.
The study’s subject matter sits at the intersection of bone biology and orthopedic complications. Wear particle-induced osteolysis remains a clinically important mechanism in implant failure, and mouse models are commonly used to study inflammatory bone loss. A paper claiming to suppress osteolysis through modulation of macrophage and osteoclast signaling can attract attention because it points toward a pharmacologic strategy for preserving bone around prosthetic material. But when the visual evidence underpinning that claim is compromised, the translational value collapses with it.
The retraction also touches a broader issue in preclinical research: mechanistic certainty can be fragile when the data package relies heavily on images. Western blots, immunostaining, and microscopy can be persuasive, but they are also vulnerable to duplication, over-processing, and mislabeling. When a study connects a compound to suppression of osteoclastogenesis, the expected standard is straightforward: each panel must represent the condition it purports to show, and each comparison must be reproducible and traceable back to original data.
PLOS One’s decision places the article outside the evidentiary chain for pyrroloquinoline quinine in this setting. Any downstream citation of the paper’s findings now requires caution, because the central experimental claims no longer stand on reliable ground. For clinicians and researchers interested in osteolysis, the retraction leaves the therapeutic question unresolved and removes one more potentially unstable data point from the literature.
The notice is also a reminder that a retraction can follow long after publication, especially when image analysis uncovers repeated or overlapping features that were not evident at the time of initial review. For readers, the practical implication is simple: preclinical claims about bone-protective therapies should be weighed against the quality of the supporting figures, not just the appeal of the mechanism. In this case, the figures failed that test.
What remains is a withdrawn report, not a dependable foundation for further work on pyrroloquinoline quinine, NFATc1, or wear particle-induced osteolysis. The paper’s scientific narrative has been removed from the active record because the published images no longer support confidence in the results.